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BACKGROUND: Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid
leukemia (CML), there is a dearth of information on their impact on patients’ health-related quality of life (HRQOL). The primary
objective of this study was to evaluate HRQOL and fatigue outcomes in patients with CML receiving first-line therapy with nilotinib.
METHODS: This was a multicenter, prospective study enrolling 130 patients with chronic-phase CML. HRQOL and fatigue were evalu-
ated with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC
QLQ-C30) and its validated Fatigue module at the baseline and then at 3, 6, 12, 18, and 24 months. The primary prespecified HRQOL
endpoints defined in the study protocol for longitudinal analysis were the Physical Functioning, Social Functioning, Role Functioning,
and Fatigue scales. The remaining scales were investigated on an exploratory basis. RESULTS: The rate of baseline compliance with the
HRQOL assessment was 95.4% (124 of 130), and the rate of overall compliance with HRQOL forms was 91%. Among the 4 prespeci-
fied primary HRQOL endpoints, statistically significant improvements over time were found for Physical Functioning (P 5 .013), Role
Functioning (P 5 .004), and Fatigue (P < .001). Clinically meaningful improvements were found already 3 months after the treatment
start. The baseline patient self-reported fatigue severity was an independent predictive factor for the achievement of a major mole-
cular response with an odds ratio of 0.960 (95% confidence interval, 0.934-0.988; P 5 .005). CONCLUSIONS: For most patients,
HRQOL improvements with nilotinib occur during the early phase of therapy and are maintained over time. Also, a more systematic
HRQOL evaluation during the diagnostic workup of CML may help to predict clinical outcomes. Cancer 2018;000:000-000. VC 2018
American Cancer Society.
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INTRODUCTION
The development of oral tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML) is a great triumph of
personalized medicine. The clinical outcomes of patients with CML have dramatically improved in comparison with pre-
vious interferon-based therapies,1 and the life expectancy of these patients now approaches that of the general
population.2
Since the introduction of the first oral TKI (ie, imatinib) approved as first-line therapy in 2003,1 the treatment of
CML has become more challenging with the development of second-generation TKIs such as nilotinib and dasatinib that
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can also be used as alternative first-line strategies.3
The results of the phase 3 randomized controlled trials
(RCTs) leading to the Food and Drug Administration
approvals of first-line nilotinib4 and dasatinib5 have
shown that both drugs provide faster and deeper molecu-
lar responses (MRs) than imatinib therapy. However, dif-
ferences in overall survival among these 3 drugs have yet
to be demonstrated.3
Therefore, first-line treatment selection is one of the
major challenges of patient management in clinical prac-
tice. The availability of multiple TKIs now also offers the
opportunity to change drugs, regardless of the type of
initial therapy, not only in patients reporting a negative
outcome during the course of therapy (eg, a loss of cytoge-
netic response) but also in those with a somewhat favor-
able outcome who have not reached an optimal
outcome.6 In such a complex scenario and because in
most cases CML therapy is lifelong, information on the
impact of these drugs on patients’ wellbeing and symptom
burden becomes critical for making more informed treat-
ment decisions.
Although a wealth of efficacy and physician-
reported safety data is available for approved first-line
TKIs, there is a dearth of information regarding patient-
reported health-related quality of life (HRQOL) out-
comes.7 Also, most of the available HRQOL studies in
CML have been confined to patients receiving imatinib
therapy,8-10 and to the best of our knowledge, no prospec-
tive HRQOL data are available on patients with CML
treated with first-line nilotinib therapy.
The primary objective of this study was to investi-
gate HRQOL and fatigue outcomes in patients receiving
first-line nilotinib therapy over a 2-year period. A second-
ary objective was to investigate the predictive value of
pretreatment patient-reported HRQOL outcomes for
achieving a clinical response.
MATERIALS AND METHODS
Study Design and Treatment
This was a Italian Group for Adult Hematologic Diseases
(GIMEMA) single-arm study of nilotinib (300 mg twice
daily) in adult patients with newly diagnosed chronic-
phase CML. Patients were included from 32 GIMEMA
centers from December 2011 to November 2012. The
results of the primary endpoint and clinical efficacy data
at 2 years have been reported previously.11 Briefly, a dose
increase to 400 mg twice daily was scheduled in case of a
suboptimal response or failure according to 2009 Euro-
pean LeukemiaNet recommendations.12 Pretreatment
with hydroxyurea or anagrelide for a duration of up to 3
months and pretreatment with imatinib for up to 30 days
were permitted. The MR was assessed by peripheral blood
reverse transcription–polymerase chain reaction at selected
GIMEMA LabNet laboratories able to express the results
according to the International Scale.13 Adverse events were
graded according to the National Cancer Institute’s Com-
mon Terminology Criteria for Adverse Events (version
4.0). The risk scores were calculated according to the
Sokal,14 Euro,15 and European Treatment and Outcome
Study formulations.16 The HRQOL assessment over a 2-
year period was a prespecified secondary endpoint of the
research protocol, and we herein report the full analysis.
The study protocol was approved by the ethics com-
mittees of all participating centers and was conducted in
accordance with the Declaration of Helsinki. All patients
provided written informed consent. This study is regis-
tered at ClinicalTrials.gov (NCT01535391).
Procedures for HRQOL and Fatigue Assessment
HRQOL was assessed with the European Organization
for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 (EORTC QLQ-C30).17 This is a
self-reported questionnaire whose validity and test-retest
reliability have been demonstrated in several studies.18
The EORTCQLQ-C30 consists of 30 items and includes
5 functional scales (Physical, Role, Emotional, Social, and
Cognitive), 3 symptoms (fatigue, nausea and vomiting,
and pain), a global health status/quality-of-life scale, and
6 single items (dyspnea, insomnia, appetite loss, constipa-
tion, diarrhea, and financial difficulties). The raw scores
of the questionnaire are transformed into a linear scale
ranging from 0 to 100, with a higher score representing
either a higher level of functioning and health status/qual-
ity-of-life or a higher level of symptoms. In the study pro-
tocol, fatigue was assessed with the validated EORTC
Quality of Life Questionnaire-Fatigue 13 (QLQ-
FA13).19 However, for the purpose of this analysis, out-
comes are reported according to the most recent valida-
tion of this questionnaire, which resulted in the EORTC
Quality of Life Questionnaire-Fatigue 12 (QLQ-FA12)
and was based on the recommended EORTC scoring
algorithm20 (therefore, we herein refer to the EORTC
QLQ-FA12). Because of the multidimensional nature of
fatigue, this questionnaire consists of the following 5
domains: Physical, Cognitive, and Emotional Fatigue as
well as Interference With Daily Living and Social
Sequelae. In this questionnaire, a higher score (range,
0-100) represents a greater impairment in the correspond-
ing domain.
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The protocol stipulated that HRQOL and fatigue
had to be assessed at the baseline (ie, before the treatment)
and then at 3, 6, 12, 18, and 24 months. These time
points were a priori selected on the basis of clinical rele-
vance as associated with an assessment of clinical efficacy
endpoints.
Because of the importance of the mode of HRQOL
questionnaire administration to data quality,21 standard
operating procedures for administering questionnaires
were included in the study protocol to ensure homogene-
ity in data collection among all participating centers.
Statistical Analysis
The primary prespecified HRQOL endpoints defined in
the study protocol for longitudinal analysis were the Phys-
ical Functioning, Social Functioning, Role Functioning,
and Fatigue scales from the EORTC QLQ-C30. The
remaining scales were investigated on an exploratory basis.
Fisher’s exact test and the Wilcoxon-Mann-Whitney test
were used as appropriate to assess differences between sub-
groups. We estimated mean HRQOL patterns over time
with a linear mixed model with an unstructured covari-
ance structure, and we reported means, standard devia-
tions, and corresponding 95% confidence intervals for
any HRQOL assessment. For each scale, we tested the
null hypothesis of no global change from the baseline with
an overall F test. We also considered the minimally
important difference (MID) in HRQOL outcomes,
which can be considered the smallest change in an out-
come that a patient would identify as important and is not
necessarily related to statistical significance.22 Clinically
meaningful improvements from the baseline were, there-
fore, evaluated for both the EORTCQLQ-C3017 and the
EORTC QLQ-FA12.20 For the EORTC QLQ-C30, the
MID for each scale was defined according to specific
thresholds reported by Cocks et al23 for this question-
naire. The clinical significance of scales of the EORTC
QLQ-FA12 was based on previous work by Norman
et al24 because no specific guidelines are yet available to
determine the MID for this questionnaire. On the basis of
previous work,25,26 we used MIDs to assess the time until
a definitive HRQOL improvement as measured from the
date of the baseline HRQOL to that of the first achieve-
ment of a clinically meaningful HRQOL improvement
(from the baseline), with no further impairment of more
than an MID.27 We used the Cox proportional hazards
model with the Fine-Gray method, and we considered
failure, a suboptimal response, disease progression, and
toxicity as possible competing events. Patients were cen-
sored at the date of either the last follow-up or last
HRQOL questionnaire completion if they had experi-
enced neither a definitive HRQOL improvement nor a
competing event within 2 years of follow-up. For each
scale, we calculated the proportions of patients achieving a
definitive HRQOL improvement and the corresponding
cumulative incidence curves for the time until a definitive
HRQOL improvement. As specified in the protocol, the
predictive value of baseline HRQOL scores for traditional
clinical responses (including a major molecular response
[MMR]) was also examined. Univariate and multivariate
logistic regression analyses were used. When performing
multivariate analyses, we included key baseline clinical
and demographic variables as possible confounders: age at
diagnosis, sex, hemoglobin level, Eastern Cooperative
Oncology Group performance status, comorbidity, previ-
ous treatment, dose reduction/interruption (at least once),
and Sokal risk. Two multivariate models were considered:
one using each component of the Sokal risk (to more thor-
oughly examine the actual predictive value of HRQOL
outcomes against key laboratory variables) and another
using the computed Sokal risk group categories.
We performed sensitivity analyses to identify possi-
ble systematic missing data–generating mechanisms. We
used logistic regression analysis to evaluate the possible
impact on the missingness of baseline characteristics and
HRQOL at any time point and of previously observed
HRQOL at the next assessment. We also graphically
inspected mean HRQOL patterns over time. Statistical
significance was set at a5 .05 for all analyses, which were
performed with SAS statistical software (version 9.4; SAS
Institute, Cary, North Carolina) and R software (version
3.2.4).
RESULTS
One hundred thirty patients were enrolled in this study,
and full results for clinical and efficacy data have been
published elsewhere.11 Briefly, at 24 months, 65% of the
patients had an MMR, and among the nonhematologic
and noncardiovascular adverse events, the following low-
grade (ie, grade 1 or 2) adverse events were reported in
more than 10% of the patients: fatigue (17%), bone and
muscle and joint pain (22%), and skin rash (29%).
Baseline HRQOL Characteristics and
Compliance Over Time
The baseline rate of compliance with the HRQOL assess-
ment was 95.4% (124 of 130), and patients’ characteris-
tics are reported in Table 1. The overall rate of
compliance with the HRQOL forms was 91%, and details
on compliance over time are reported in Table 2.
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No statistically significant difference existed between
patients with (n5 124) and without a baseline evaluation
(n5 6) with respect to key sociodemographic and clinical
characteristics. Also, there were no statistically significant
differences in baseline HRQOL characteristics by the
Sokal risk at diagnosis (Supporting Table 1) or by previ-
ous therapy (Supporting Table 2), and this indicated that
HRQOL outcomes over time were not affected by this
variable.
Longitudinal Analysis of HRQOL Outcomes Over
Time
Of the 4 prespecified primary HRQOL outcomes, only
Social Functioning did not show a statistically significant
change over time (P 5 .512). Statistically significant
improvements over time were found for Physical Func-
tioning (P 5 .013), Role Functioning (P 5 .004), and
Fatigue (P < .001; Fig. 1). In these 3 scales, a clinically
meaningful improvement (albeit small) was found already
3 months after the treatment start. Other significant
improvements in EORTC QLQ-C30 scales were found
for Global Health Status/HRQOL (P< .001), Emotional
Functioning (P 5 .004), Nausea and Vomiting (P 5
.003), and Appetite Loss (P5 .002). Also, statistically sig-
nificant improvements in the Physical (P < .001) and
Cognitive Fatigue scales (P 5 .014) of the EORTC
QLQ-FA12 were found. HRQOL trajectories over time
for select secondary scales are reported in Figure 2.
Analysis of Time Until a Definitive Improvement
in HRQOL Outcomes
Overall, 58% of the patients (72 of 124) achieved, at any
time point during the study, a clinically meaningful
improvement in the Global Health Status/HRQOL scale
(EORTC QLQ-C30) that was maintained throughout
the study period. The 3 other largest proportions of defin-
itive improvements were found for Emotional Function-
ing, Fatigue, and Physical Functioning: 54% (67 of 124),
48% (59 of 124), and 36% (45 of 124), respectively.
Already 6 months after the baseline assessment, 37% of
the patients (46 of 124) reported definitive improvements
in fatigue. Details are reported in Figure 3.
Sensitivity Analyses
A graphical inspection of the mean scores of HRQOL
scales over time by the number of assessments did not sug-
gest missing-not-at-random data. When we investigated a
possible missing-at-random mechanism by logistic regres-
sion analysis, neither sociodemographic nor clinical pre-
treatment variables showed a statistically significant
impact on missingness at any time point. These variables
included age, sex, comorbidity, hemoglobin level, white
blood cell count, blasts, Sokal risk score, Eastern Coopera-
tive Oncology Group performance status, and the receipt
of previous treatment for CML. Pretreatment HRQOL
scores were also not significant in predicting missingness
TABLE 1. Patient Characteristics (n 5 124)
Characteristic Value
At diagnosis
Age, median (range), y 49.5 (18-81)
Sex: male, No. (%) 80 (64.5)
ECOG performance status  1, No. (%) 20 (16.1)
Hb level, median (range), g/dL 12.0 (7.6-16.3)
Platelet count, median (range), 3103/L 396 (101-4093)
Spleen, median (range), cm 1.0 (0-26)
Blast cells in PB, median (range), % 1.0 (0-14.0)
Eosinophils in PB, median (range), % 2.0 (0-10.0)
Basophils in PB, median (range), % 2.4 (0-13.0)
Sokal score, No. (%)
Low 53 (43)
Intermediate 45 (36)
High 26 (21)
Euro score, No. (%)
Low 57 (46)
Intermediate 60 (48)
High 7 (6)
EUTOS score, No. (%)
Low 114 (92)
High 10 (8)
Comorbidity, No. (%)
No 50 (40)
Yes 74 (60)
Before nilotinib start
Previous therapy, No. (%)
No 50 (40)
Yes 74 (60)
If yes to previous therapy, No. (%)
Hydroxyurea 67 (91)
Imatinib 7 (9)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EUTOS, Euro-
pean Treatment and Outcome Study; Hb, hemoglobin; PB, peripheral
blood.
TABLE 2. HRQOL Compliance Over Time
HRQOL Questionnaire T0 (Baseline) T1 (3 mo) T2 (6 mo) T3 (12 mo) T4 (18 mo) T5 (24 mo)
Expected, No. 130 126 120 115 112 104
Complete, No. 124 118 113 102 102 84
Compliance, % 95.4 93.7 94.2 88.7 91.1 80.8
Abbreviation: HRQOL, health-related quality of life.
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at any time point, and previous HRQOL scores were not
statistically significant for missingness at a subsequent
evaluation. These results allow us to be confident in the
robustness of the final findings about HRQOL patterns
over time.
Predictive Value of Baseline HRQOL Outcomes
for the Achievement of an MR
The results of a univariate analysis investigating the pre-
dictive value of baseline HRQOL and fatigue outcomes
for the achievement of an MR (ie, MMR, MR4.0, and
MR4.5) showed that patients with greater physical fatigue
severity (EORTC QLQ-FA12) at the baseline were less
likely to achieve an MMR (odds ratio [OR], 0.975; 95%
confidence interval, 0.956-0.995; P 5 .016). No other
scales were statistically significant in the univariate analy-
sis. No association was found between baseline fatigue
and the achievement of MR4.0 or MR4.5. The proportions
of dose reduction/interruption in patients with higher
fatigue (ie, equal to or greater than the median value of 20
points) or lower fatigue (ie, less than 20 points) were
32.3% (21 of 65) and 22% (13 of 59), respectively (P 5
.230).
A multivariate analysis, controlling for age, sex,
hemoglobin level, spleen size, platelet count, blast cells,
performance status, comorbidity, previous treatment, and
dose reduction/interruption, was also performed, and it
confirmed the independent predictive value of a patient’s
self-reported fatigue severity with an OR of 0.960 (95%
confidence interval, 0.934-0.988; P 5 .005) for the
achievement of an MMR (Table 3). This OR of 0.960
indicates a 40% decrease in the odds to achieve an MMR
at any time point with every 10-point increase (ie, worsen-
ing) in the baseline fatigue scale. A multivariate analysis
was also performed with Sokal risk groups (in place of sin-
gle components of the score), and fatigue still remained
statistically significant in the final model (Supporting
Table 3).
For descriptive purposes, the baseline HRQOL and
fatigue profile of patients who eventually achieved an
MMR at least once (n 5 95) versus those who did not
(n5 23) is reported in Supporting Figure 1.
DISCUSSION
This study shows that newly diagnosed patients with
CML who are starting first-line therapy with nilotinib
report a number of HRQOL improvements over time in
comparison with their baseline health conditions.
Clinically meaningful improvements were found
already at 3 months in 3 of the 4 a priori selected scales for
Figure 1. Mean patient-reported HRQOL and 95% confidence intervals over 2 years on prespecified primary scales (European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30). Higher scores on the Physical Func-
tioning, Role Functioning, and Social Functioning scales indicate better HRQOL outcomes. Higher scores on the Fatigue scale
indicate a higher severity of fatigue. CI indicates confidence interval; HRQOL, health-related quality of life.
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the primary analysis: Fatigue, Physical Functioning, and
Role Functioning. Our study was designed to address not
only general HRQOL aspects but also fatigue with a well-
validated measure19,20 that confirmed a statistically signif-
icant reduction of physical and cognitive fatigue severity
over time. Previous work indicated that fatigue is a main
concern for patients with CML receiving TKIs28,29; there-
fore, our findings provide further evidence that nilotinib
therapy might contribute to improved key patient out-
comes. Also, our additional analysis investigating defini-
tive improvements over time revealed that some 60% of
patients reported a clinically meaningful benefit on the
global HRQOL scale that was maintained over the 2-year
period of observation. This finding suggests that for most
patients treated with nilotinib, HRQOL benefits are not
transient and can be maintained over time. Very little pro-
spective information exists on the impact of TKIs on
long-term HRQOL outcomes; therefore, it is difficult to
put our results into a larger perspective. However, in a
recent study of patients with CML with 264 weeks or
more of follow-up who were mainly treated with second-
or third-line bosutinib therapy, Kantarjian et al30 also
demonstrated that patients’ wellbeing can be preserved
over the long term.
Two recent studies described HRQOL outcomes of
patients with CML receiving nilotinib therapy as second-
Figure 2. Mean patient-reported HRQOL and 95% confidence intervals over 2 years on selected secondary scales. Higher scores
on the Global Health Status/QOL and Emotional Functioning scales indicate better HRQOL outcomes. Higher scores on all other
scales indicate worse outcomes. CI indicates confidence interval; EORTC, European Organisation for Research and Treatment of
Cancer; HRQOL, health-related quality of life; QLQ-C30, Quality of Life Questionnaire Core 30; QLQ-FA12, Quality of Life Ques-
tionnaire Fatigue 12.
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line therapy. Sacha et al31 documented the effects of nilo-
tinib used as second-line therapy for chronic-phase CML
over a 1-year period in patients switching mainly from
imatinib therapy because of intolerance and/or resistance,
and HRQOL was evaluated with the same questionnaire
used in our study. Although a direct comparison with our
findings is not possible because of major differences in the
study design and statistical analysis, we note that nilotinib
therapy was also found to improve some HRQOL out-
comes. However, the magnitude of these improvements
was smaller than that found in our analysis, and this could
be explained by the greater burden of previous TKI thera-
pies and a substantially longer time since diagnosis (mean
time, 4.5 years). Cortes et al32 found that switching to
nilotinib therapy is a valuable strategy for reducing the
symptom burden and improving HRQOL in imatinib-
treated patients who have experienced low-grade, nonhe-
matologic adverse events. Although the median duration
Figure 3. Time until definitive improvement on selected scales of health-related quality of life. When we calculated the cumulative
probability of achieving a definitive improvement, we accounted for competing risks, which were defined as failure, a suboptimal
response, disease progression, and toxicity.
TABLE 3. Multivariate Logistic Regression Analysis
for the Achievement of a Major Molecular
Response
Variable OR (95% CI) P
Age at diagnosis (y)a 0.982 (0.937-1.030) .459
Sex: male 0.486 (0.129-1.832) .286
Patient-reported fatigueb 0.960 (0.934-0.988) .005
Hb level (g/dL) 0.992 (0.691-1.424) .965
Spleen (cm)a 0.827 (0.730-0.938) .003
Platelet count (3103/L)a 1.003 (1.000-1.007) .057
Blast cells (%)a 1.046 (0.747-1.466) .793
ECOG performance status 1 0.284 (0.058-1.379) .118
Comorbidity 0.621 (0.140-2.766) .532
Previous treatment 2.608 (0.644-10.561) .179
Dose reduction/interruption 0.474 (0.143-1.572) .222
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncol-
ogy Group; Hb, hemoglobin; OR, odds ratio.
a Component of the Sokal risk score.
b Patient-reported Physical Fatigue scale assessed with the Quality of Life
Questionnaire-Fatigue 12 (QLQ-FA12) from the European Organisation for
Research and Treatment of Cancer.
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time of previous imatinib therapy was 31 months, benefits
from switching to nilotinib therapy were already found at
the end of the first cycle of therapy.
Another finding of our study was that patients with
a greater burden of pretreatment fatigue were less likely to
achieve an MMR. This finding remained significant in
the multivariate analysis when we controlled for key
potential confounders. Our results might be corroborated
by several studies of other solid and hematologic malig-
nancies,33 which have found that patient self-reported
symptoms, including fatigue, provide independent prog-
nostic information for survival outcomes beyond well-
established disease-related factors.34-36 In the CML arena,
our findings are partly consistent with 3 studies published
in an abstract form37-39 that indicate that a patient’s
health status, as measured by validated HRQOL instru-
ments, can provide unique clinically relevant information.
Beaumont et al37 found that baseline HRQOL was pre-
dictive for treatment discontinuation but not for an MR
in patients receiving first-line imatinib or nilotinib. How-
ever, it is challenging to compare our findings with this
study because their analysis did not distinguish by the
type of TKI, and this hampers disentangling the possible
effects of drugs on study outcomes. In addition, all their
patients were enrolled in an RCT setting,4 and they thus
possibly represented a more select patient population than
the one included in our study. Nicolini et al38 analyzed
the predictive value of HRQOL in a population of
patients with CML for whom imatinib failed and who
switched to either dasatinib or nilotinib. They found that
failure-free survival was significantly longer for patients
with higher HRQOL scores at the time of switching the
TKI from imatinib therapy. Another recent study by Ion-
ova et al39 found that baseline HRQOL was predictive for
the achievement of a complete cytogenetic response and
MMR in patients with CML treated with dasatinib as
first- or second-line therapy.
It is possible to speculate that the patients with
higher baseline fatigue in our study were those with a
greater disease burden and that this cannot be fully cap-
tured with traditional clinical examinations or physician-
reported tools such as the performance status. Rather,
well-validated patient-reported outcome measures might
be more sensitive indicators of the overall disease burden.
Further research is needed to elucidate underlying reasons
for this relation and to investigate possible mediating fac-
tors. Anyway, current findings underscore the value of a
more systematic HRQOL evaluation during the diagnos-
tic workup.
A limitation of this study is that we cannot directly
compare the HRQOL outcomes of our patients with
those of patients receiving other first-line TKIs. Future
comparative studies are needed to contrast HRQOL out-
comes with various TKIs. Also, although we found that
baseline fatigue predicted MMR, we could not demon-
strate this association with a deeper MR (MR4.0 and
MR4.5). This might be due to the short period of observa-
tion, and longer follow-up is needed to better ascertain
this relation in future analyses.
This study also has notable strengths. Because it is a
multicenter academic and non-RCT study, our findings
are likely to be highly generalizable to the wider CML
population most typically seen in a real-world setting.
Also, we included a well-validated measure of fatigue,19,20
which is a critical concern for patients with CML.
In conclusion, our results extend our knowledge of
the efficacy and safety of frontline nilotinib therapy by
providing the patient’s perspective of the impact of this
drug on his or her HRQOL and symptom burden. Our
findings may help physicians to make more informed
treatment decisions at the time of starting CML therapy
with TKIs.
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